Related Experiment Video
Updated: May 14, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Adherence and completion in hepatitis C management: a systematic review
Rhoda Redulla1, Sharon Dudley-Brown
1Department of Nursing Education, Innovation & Professional Development, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Rhoda.Redulla@uphs.upenn.edu
Summary
Managing Hepatitis C virus (HCV) medication requires integrated strategies to overcome treatment challenges like side effects. This review explores current HCV management science and adherence models.
Area of Science:
- Hepatology
- Infectious Diseases
- Pharmacotherapy
Background:
- Hepatitis C virus (HCV) treatment presents significant complexities.
- Patient adherence and treatment completion are critical for successful outcomes.
- Managing HCV medication requires addressing patient-reported symptoms and side effects.
Purpose of the Study:
- To appraise the current scientific landscape of HCV management.
- To evaluate models supporting treatment completion and adherence in HCV therapy.
- To identify limitations in current evidence and suggest future research directions.
Main Methods:
- Literature review and synthesis of current scientific evidence on HCV management.
- Analysis of existing models for enhancing treatment adherence and completion.
- Critical appraisal of the strengths, weaknesses, and limitations of the evidence base.
Main Results:
- HCV therapy is complex, often hindered by patient symptoms (anemia, depression, fatigue).
- Various management models exist, but their effectiveness in ensuring adherence needs further evaluation.
- Current evidence has identified strengths, weaknesses, and limitations impacting patient compliance.
Conclusions:
- A comprehensive, integrated approach is essential for effective Hepatitis C virus management.
- Addressing patient-symptom burden is key to improving medication adherence and treatment success.
- Further research is needed to refine HCV management strategies and optimize patient outcomes.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...